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Abstract
Purpose—To report, from Cancer and Leukemia Group B Protocol 9082, the impact of high-
dose cyclophosphamide, cisplatin, and BCNU (HD-CPB) vs. intermediate-dose CPB (ID-CPB) on
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the ability to start and complete the planned course of local–regional radiotherapy (RT) for women
with breast cancer involving ≥10 axillary nodes.
Methods and Materials—From 1991 to 1998, 785 patients were randomized. The HD-CPB
and ID-CPB arms were balanced regarding patient characteristics. The HD-CPB and ID-CPB arms
were compared on the probability of RT initiation, interruption, modification, or incompleteness.
The impact of clinical variables and interactions between variables were also assessed.
Results—Radiotherapy was initiated in 82% (325 of 394) of HD-CPB vs. 92% (360 of 391) of
ID-CPB patients (p = 0.001). On multivariate analyses, RT was less likely given to patients who
were randomized to HD treatment (odds ratio [OR] = 0 .38, p < 0.001), older (p = 0.005), African
American (p = 0.003), postmastectomy (p = 0.02), or estrogen receptor positive (p = 0.03). High-
dose treatment had a higher rate of RT interruption (21% vs. 12%, p = 0.001, OR = 2.05),
modification (29% vs. 14%, p = 0.001, OR = 2.46), and early termination of RT (9% vs. 2%, p =
0.0001, OR = 5.35), compared with ID.
Conclusion—Treatment arm significantly related to initiation, interruption, modification, and
early termination of RT. Patients randomized to HD-CPB were less likely to initiate RT, and of
those who did, they were more likely to have RT interrupted, modified, and terminated earlier than
those randomized to ID-CPB. The observed lower incidence of RT usage in African Americans
vs. non–African Americans warrants further study.
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Introduction
Most women with breast cancer present with local–regional disease (breast with or without
the regional axillary nodes), without evidence of distant systemic disease. The risk of
subsequent systemic relapse is related to the extent of axillary disease (1–4). Among patients
with ≥10 involved axillary nodes at presentation, approximately 50–90% will relapse
systemically within 5 years despite conventional adjuvant chemotherapy (5, 6).
Some studies (7–9), albeit not all (10, 11), suggest that chemotherapy intensity might
influence its ability to sterilize subclinical distant metastases. Toward this goal, a series of
patients with ≥10 positive axillary nodes were treated on a Phase II study with four cycles of
conventional-dose CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil) followed by
high-dose cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
(HD-CPB) with autologous bone marrow support (Cancer and Leukemia Group B [CALGB]
Protocol 8782). The 3-year relapse-free survival rate was 72% (12), better than in historical
controls.
This observation led to a multi-institution, intergroup, randomized, Phase III study (CALGB
9082, Southwest Oncology Group 9114, National Cancer Institute of Canada MA-13) to test
this approach in patients with ≥10 positive axillary nodes. After surgical removal of all gross
disease, patients received initial CAF chemotherapy, followed by randomization to either
HD-CPB or intermediate doses of the same drugs (ID-CPB). Preliminary analysis, with a
median 3-year follow-up, suggested a reduction in breast cancer relapses but an increase in
treatment-related mortality in the HD-CPB arm compared with the ID-CPB arm. Overall
survival rates were equivalent in the two arms (13, 14).
All patients in this study were prescribed to receive local–regional radiotherapy (RT) after
chemotherapy. We herein report the impact of HD-CPB vs. ID-CPB on the ability to start
and complete the planned course of local–regional RT. Other clinical variables that might be
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associated with omission of the planned RT were also considered. This is an important issue
because local–regional RT dramatically reduces the risk of locoregional relapse, reduces the
risk of systemic relapse, and improves overall survival (15–25). Therefore, modifications in




The trial was open to accrual between January 1991 and May 1998; details reported
elsewhere (14). Eligibility criteria included (1) age ≥18 years with operable non–locally
advanced/inflammatory breast adenocarcinoma involving ≥10 axillary nodes, but without
evidence of distant metastases (negative results on bilateral bone marrow biopsies and
aspirates, bone scan, and chest, abdomen, pelvis, and brain CT scans); (2) resection of all
gross disease by mastectomy (radical or modified radical) or lumpectomy with Level I to II
axillary dissection; (3) negative surgical margins (lymphatic and vascular involvement was
permitted) (pathologic stage T1–3, N1–2; American Joint Committee on Cancer 1988
criteria); (4) Eastern Cooperative Oncology Group performance score of 0–1; (5) no
previous chemotherapy or RT; and (6) not pregnant. Patients with prior or concomitant
malignancies, other than curatively treated carcinoma in situ of the cervix or nonmelanotic
skin cancer, were not eligible. Patients with serious comorbid diseases that would have
negatively affected their tolerance for therapy were not eligible. Patients with synchronous
bilateral breast cancers were eligible. Patients provided written, informed consent to
participate in the study.
Treatment
Systemic therapy—Protocol treatment included three cycles of adjuvant CAF
chemotherapy followed by randomization to a fourth cycle of CAF plus HD-CPB or a fourth
cycle of CAF plus ID-CPB (Fig. 1) (14). Patients were restaged approximately 6 weeks after
completion of all chemotherapy. The protocol-prescribed RT was to be delivered in all
patients provided there was no evidence of systemic disease at restaging. Patients with
positive/unknown hormone receptor status were to receive tamoxifen for 5 years starting 7
weeks after the initiation of CPB. In many patients, tamoxifen was not started until after RT
(Fig. 1).
Radiotherapy—Sites to be irradiated included the ipsilateral breast/chest wall and
supraclavicular lymph nodes. Irradiation of the axilla was not recommended but was
permitted at the discretion of the treating radiation oncologist. Treatment of the internal
mammary nodes (IMN) was strongly recommended, though not required.
Three treatment techniques were given as options: (1) Technique A: tangent breast/chest
wall fields with or without IMN. In some cases, partly wide tangent fields were used that
included the superior but not the inferior IMN chain, to reduce incidental irradiation to the
heart (26). To consider the possible effect of inclusion of IMN within the RT fields on
outcome, patients were further subdivided by IMN dose <30 Gy (Technique A1) or ≥30 Gy
(Technique A2). The 30-Gy threshold was chosen on the basis of human clinical studies
suggesting that doses of ≥25 Gy can be associated with lung injury. (2) Technique B:
anterior or anterior-oblique electron/photon IMN field with tangent photon breast/chest wall
fields. (3) Technique C: en face chest wall and IMN electron fields (not appropriate for
patients undergoing lumpectomy), with bolus as clinically indicated.
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For all techniques, CT planning was recommended to assess IMN location and for
dosimetry. Cobalt-60 and high-energy photons between 4 and 15 MV were used to treat the
supraclavicular and axillary nodes, and the chest wall (and IMN) for patients receiving
Techniques A and B. Electron energy was selected at the discretion of the treating physician
to provide homogeneous coverage to the target volume. Wedges and bolus were used as
necessary. A separate anterior medial oblique supraclavicular field (angled approximately
15° to the contralateral side; i.e., medial-anterior oblique) was used. This angulation was
recommended to provide adequate coverage of the medially placed nodes without exiting
into the spine. Field borders were as follows: inferior—inferior to the clavicular head and
matched to the superior border of the breast/chest wall field; medial—medial to the
sternocleidomastoid muscle; superior—at the level of the cricoid cartilage; and lateral—at
the medial extent the axillary surgery, or at approximately the coracoid process or medial
humeral head. Treatment of the full axilla, by extending the lateral border of this
supraclavicular field into the axilla, and the use of posterior axillary boost were not
recommended but were permitted.
All sites were to be treated to 50.4 Gy at 1.8 cGy per fraction. The prescription point for the
supraclavicular field was 3 cm, or at the depth of the supraclavicular vessels as measured on
CT imaging. An additional 10 Gy in 5 fractions with electrons was prescribed to the region
of the mastectomy scar or tumor bed. This could be omitted at the physician's discretion for
patients who had breast reconstruction.
Submission of patient therapy data
Patient registration and data collection were managed by the CALGB Statistical Center.
Demographics and baseline clinicopathologic variables were collected before initiation of
protocol treatment. The following data were collected at regular intervals during and after
treatment: toxicity, treatment information (dosing, site of delivery, and reason for early
termination/noncompliance) for chemotherapy and RT, and disease and survival status.
These data were initially reviewed for accuracy and completeness at CALGB Data
Operations and subsequently in an independent audit process. Radiotherapy data underwent
central review by the Quality Assurance Review Center.
Statistical considerations
The relationship of demographic and baseline clinicopathologic factors to each of four
different outcomes was assessed: (1) initiation, (2) interruption, (3) modification, and (4)
completion of protocol-prescribed RT. Because the reason for the occurrence of each
outcome was not recorded, each outcome was scored as a dichotomous event, that is,
occurred or not, regardless of reason. Outcome 1 was measured for all patients randomized
to the Treatment Study 9082, whereas Outcomes 2, 3, and 4 were measured only for those
patients who began protocol RT.
Candidate explanatory variables used to model the relationship with Outcome 1 included
chemotherapeutic treatment arm (HD/ID), age at enrollment (continuous), race (African
American [AA]/non-AA), menopausal status (pre/post), tumor-related variables (estrogen
receptor [ER] status [positive/negative]), tumor size (≤5/>5 cm), number of positive nodes
(10–15/16+), and type of surgery (mastectomy/nonmastectomy). Radiotherapy technique
(A1/A2/B/C) was also included as a candidate predictor for Outcomes 2–4.
Forward stepwise logistic regression (with an α = 0.05 to enter the model) was used to study
the multivariate association of each outcome with the candidate predictors listed above.
Univariate associations were tested (α = 0.05) with the χ2-test or the Mann-Whitney U test,
as appropriate. The following interactions, selected a priori, were descriptively examined for
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associations with outcome variables: arm × technique, arm × race, arm × age, and race ×
age. On the basis of this examination, only the following interactions were subsequently
tested in the multivariate model: (1) race × age on RT initiation, and (2) arm × technique on
RT modification, interruption, and completion. In addition, for Outcomes 2–4, the
interaction of RT technique with surgery type was examined descriptively only, because it
contained a zero cell (i.e., lumpectomy patients cannot undergo RT Technique C). A two-
sided α = 0.05 was used for all statistical tests. Cancer and Leukemia Group B statisticians
performed all statistical analyses on study data stored in the CALGB database, using SAS
software (SAS Institute, Cary, NC).
Results
A total of 785 patients were randomized on CALGB 9082 (Table 1). The two arms were
well balanced in terms of patient characteristics. The median survival follow-up, measured
from randomization, for the 466 surviving patients was 7.5 years (range, 2.6–11.8 years).
The endpoints of interruption, modification, and failure to complete RT were not mutually
exclusive endpoints. Seventy-one percent (71%) of patients who began RT successfully
completed it without either interruption or modification. One hundred thirty-two (132)
patients (19%) experienced only one endpoint (interruption, 8%; modification, 10%; early
termination, 1%), whereas 8% experienced two (interruption and modification, 6%;
modification and early termination, 3%). Two percent terminated RT early with both
interruptions and modifications.
Initiation of protocol radiotherapy
Univariate and multivariate results are shown in Tables 2 and 3, respectively. Of the 785
randomized patients, 87% began protocol RT. A larger proportion of ID vs. HD patients
initiated RT (92% vs. 82%; p = 0.001). After adjusting for patient age and race, surgery
type, and tumoral ER status in multivariate logistic regression, treatment arm remained a
significant predictor of RT (odds ratio [OR] = 0.38, 95% confidence interval [CI] = 0.23–
0.61, p < 0.0001). The interaction of race × age was marginally significant in the
multivariate model (p = 0.07). Only three of the eight AAs aged ≥50 years (38%) initiated
RT, compared with much larger percentages for the 42 AAs aged <50 years (83%), the 546
Caucasians aged <50 years (90%), and the 189 Caucasians aged ≥50 years (82%).
Among those who initiated RT, the median time to start of RT (from the start of CPB) was
shorter for the ID arm than for the HD arm (50 vs. 62 days; p < 0.0001).
Interruptions in protocol RT
Of the 685 patients who began RT, 112 (16%) had their RT delivery interrupted, 21% on the
HD arm and 12% on the ID arm (p = 0.001, unadjusted OR = 2.05, 95% CI = 1.34–3.14;
Table 2). Multivariate analyses indicated that only treatment arm significantly related to RT
interruption. There was, however, a suggestion that RT technique as a main effect related to
interruption (p = 0.064). Technique C was more likely to result in RT interruption than each
of the other techniques (OR [95% CI] of C:A1, A2, and B, respectively, were 2.02 [0.96–
4.27], 2.31 [1.10–4.85], and 1.36 [0.65–2.80]).
Table 4 shows the percentage of patients whose RT was interrupted according to RT
technique and surgery type. Among nonmastectomy patients, there was no difference among
Techniques A1, A2, and B; however, among mastectomized patients, Technique C (26%)
had a slightly higher incidence of interruption than Techniques A1, A2, or B (17%, 13%,
and 20%, respectively).
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Modifications to protocol RT
One hundred forty-five (145, 21%) of the patients who initiated RT underwent modifications
to the planned RT regimen. Incidence of modification on the HD arm (29%) was more than
twice that of the ID arm (14%; p = 0.001, OR = 2.46, 95% CI = 1.68–3.61; Table 2). In
multivariate analysis, treatment arm was the only significant predictor of modification. The
most frequent reason for RT modification was RT-related toxicity for the ID arm (33%) and
chemotherapy-related toxicity for the HD arm (39%) (Table 5).
Completion of protocol RT
The noncompletion incidence on the ID arm was only 2%, compared with 9% on HD (p =
0.0001, unadjusted OR = 5.35; Table 2). In multivariate analyses, treatment arm (p =
0.0002) and RT technique (p = 0.023) significantly predicted RT noncompletion. The OR of
HD:ID on noncompletion was 5.68 (95% CI = 2.29–14.1). Technique C was more likely to
result in noncompletion than each of the other techniques (OR [95% CI] for C:A1, A2, and
B, respectively, was 2.89 [0.98–8.55], 2.50 [0.89–7.04], and 6.62 [1.80–24.2]).
Table 6 shows the incidence of noncompletion according to RT technique and surgery type.
Failure to complete RT was greatest for mastectomized patients irradiated with Technique C
(14%) compared with any of the other subgroups defined by technique and surgery (ranging
from 0 to 8%).
Reported RT-associated toxicities
The precise reason for an interruption, modification, or cessation of RT was not always clear
(Table 5). Data forms on RT-related toxicity were submitted for 681 patients (Table 7). The
most frequently reported side effect was skin related (ID: 34% vs. HD: 24%). The HD vs. ID
arms differed most in incidence of Grade ≥2 RT-associated events in the lung (7% vs. <1%),
anemia (8% vs. <1%), and thrombocytopenia (9% vs. <1%). Other events were infrequent.
Although these events were scored as RT-associated, they likely were also related to the
prior chemotherapy.
Discussion
Initial data from CALGB 9082, with modest follow-up, suggests that HD-CPB does not
provide an advantage with regard to overall survival compared with ID-CPB (13, 14).
Interestingly, there seems to be a small improvement in breast cancer–specific survival in
the high-dose arm that was offset by treatment-related mortality. High-dose chemotherapy
can be toxic (12, 14, 27–30). With improvements in our ability to prevent and manage these
morbidities, high dose may provide some therapeutic advantage. At present the majority of
available data do not support the routine use of high-dose chemotherapy for patients with
breast cancer (31–33).
The present analysis suggests that HD-CPB hinders the ability to deliver RT, compared with
ID-CPB. This difference is not related to any pretreatment factors, and it persists in
subgroups defined by race, age, and RT technique. This observation is noteworthy because
RT plays an important role in the care of patients with breast cancer. Postlumpectomy RT
reduces the risk of in-breast recurrences by approximately 80% (34–36). Postmastectomy
RT reduces the risk of local–regional recurrence by approximately 67% and improves
overall survival by 5–12% (15–25, 37). Therefore, alterations in the chemotherapy regimen
that hinder the ability to deliver radiation might negatively impact on disease-free and
overall survival. However, in CALGB 9082 the relapse-free survival in the HD group was
higher than in the ID group (14), suggesting that possible detrimental effects on disease
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control resulting from the limitations on the RT delivery were offset by the possible
additional anticancer effects afforded by the HD therapy.
The relevance of the current data set can be questioned, given that high-dose chemotherapy
and bone marrow rescue is not typically performed for patients with multi-node-positive
breast cancer at present. Nevertheless, this approach may have some utility in certain subsets
of patients (e.g., young patients), and the findings from the present project might be
applicable if this therapy were to make a resurgence. Furthermore, there is continued interest
in intensifying chemotherapy regimens for some subsets of patients, as evidenced by the use
of dose-dense chemotherapy regimens (38), and the use of combined anthracycline/taxane
regimens (39). Therefore, the potential impact of these more-intensive chemotherapy
regimens on the ability to deliver subsequent postchemotherapy radiation may be relevant as
well.
Radiation technique
It is not clear why Technique C was associated with a higher rate of treatment interruption
and failure to complete treatment (Tables 4 and 6). The use of en face chest wall electrons is
a well-accepted technique and was used in the Danish trials demonstrating an improved
survival with postmastectomy RT (18, 40–41). Fewer patients were treated with Technique
C than the other techniques; additionally, the technique was not used on lumpectomy
patients. This made robust comparisons difficult. This finding may reflect physician practice
patterns regarding the use of different RT techniques and their tendency to alter an initiated
course of RT. A review of RT techniques among participating institutions did not reveal any
obvious systematic differences. Nevertheless, this observation may be due to the preferential
use of Technique C in patients with a lot of chemotherapy-associated toxicity. The exact
cause of an interruption or failure to complete therapy was not systematically recorded and
often is multifactorial. Therefore, the degree to which, for example, increased skin toxicity
may have been seen in the electron patients is not known.
Among patients treated with Technique A, there were no statistically significant differences
in the rates of interruption or completion between those in whom the IMN dose was
estimated to be <30 Gy vs. ≥30 Gy. Treatment of the IMN tends to increase irradiated lung
volumes, suggesting that lung irradiation was not the major cause for treatment
modifications. However, because IMN treatment was not assigned randomly, this may not
be a valid conclusion. Furthermore, given interpatient anatomic variability, inclusion of the
IMN within the tangent fields does not always translate into a larger volume of incidentally
irradiated lung (42).
In this analysis, patients treated with mastectomy and lumpectomy were combined. This is
reasonable given that the RT fields in the postlumpectomy and postmastectomy settings are
essentially equivalent. One would not therefore expect the rates of, for example, treatment
modification and interruption, to be related to the presence/absence of an intact breast. It is
nevertheless possible that physicians use a different threshold for interruption/modification/
suspension of RT in postlumpectomy vs. postmastectomy settings. Similarly, some of the
observed results (HD vs. ID) may be due to the application of more conservative thresholds
(e.g., more likely to use a treatment interruption) in patients that have received more
aggressive chemotherapy (i.e., with a more troubling toxicity profile).
Postmastectomy and postlumpectomy RT are generally well tolerated. Acute RT-associated
morbidity requiring treatment interruption or modification in the planned RT is unusual.
Therefore the 12% rate of treatment interruption in the ID-CPB cohort might be higher than
would be expected. It is possible that the chemotherapy regimen in the control arm of this
study was more aggressive than conventional chemotherapy. The majority of modifications
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seem to have been treatment related. However, treatment interruptions were liberally scored
to include events such as machine breakdown and the development of systemic disease,
suggesting that the reported rate may be artificially high.
Prior Phase I–II studies suggest that it is more difficult for patients to complete local–
regional RT after high-dose chemotherapy than after conventional-dose chemotherapy. In
the Phase I–II pilot study of the HD-CPB regimen (CALGB 8782), radiotherapy was
interrupted or discontinued in 9 of 40 irradiated patients (22%) (43)—a rate similar to the
21% interruption rate observed in the HD-CPB arm of the present study. Several other
reports of non-randomized patients receiving HD-chemotherapy along with RT do not note
similar RT-compliance issues (44–46). However, inter-study differences make comparisons
difficult.
Influence of other clinical factors
Radiotherapy was more likely to be initiated in patients who were younger, non-AA,
underwent lumpectomy, or had ER-negative tumors. It is logical that younger patients were
more likely to start RT because the benefits of RT are often considered to be more relevant
in younger women. Furthermore, younger patients may be more motivated, healthy, and
interested in receiving the prescribed RT compared with older women. Similarly, the impact
of type of surgery on RT initiation is expected. Postlumpectomy RT is more widely accepted
as an important component of cancer care than is mastectomy RT (whose value is more
often questioned). The increased use of RT in the ER-negative patients (vs. ER-positive)
may be due to the fact that these patients will not derive the anticancer benefits afforded by
hormonal therapy, and thus the RT may be considered to be relatively more important.
The observation that the rate of delivering RT according to protocol was influenced by race
was unexpected. African American patients received RT less frequently than non-AA
patients in both the HD-CPB and ID-CPB arms. This finding is independent of the other
baseline clinical/pathologic variables, namely, type of surgery, extent of axillary disease,
tumor size, age, or menopausal status. Therefore, race does seem to be an independent factor
for whether a patient initiated RT according to protocol. Once patients started RT, however,
there was no impact of race on the frequency of modification or failure to complete the
planned RT.
The impact of race on the receipt of therapy has been considered in several settings. Studies
of men with prostate cancer and women with breast cancer suggest that Caucasians and AAs
seemed to have received comparable treatments (45–50). However, AAs seem to be less
likely than Caucasians to undergo surgery for early-stage lung cancer (51), coronary
revascularization procedures (52, 53), breast cancer screening (54–56), and renal
transplantation (57). Non–guideline-concordant adjuvant chemotherapy regimens were more
frequently used in AA women, which might contribute to less favorable outcomes in these
populations (58). Therefore, systematic differences related to race might exist. Most studies
addressing this issue rely on epidemiologic information in large databases. Patient
candidates for a particular procedure are identified, and the incidence of the procedure is
calculated in racial subgroups. Although care is taken to try to compensate for nonracial
differences between patients, this might be difficult. In the present study, patients were
enrolled onto a prospective clinical trial that prescribed RT to be delivered. This is a
fundamentally different type of data set and may suggest racial biases. On the basis of these
findings from CALGB 9082, similar analyses in other cooperative group studies should be
considered to further address this interesting observation.
This study suggests that the delivery of postoperative local–regional RT can be
compromised by the use of high-dose chemotherapy. Because such RT improves both local
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control and survival, future clinical trials of adjuvant high-dose chemotherapy should
carefully consider this issue.
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Scheme of Cancer and Leukemia Group B Protocol 9082. RT = radiotherapy.
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Table 1
Patient demographics and baseline disease characteristics by treatment arm
Treatment arm
Characteristic HD-CPB ID-CPB
Total randomized 394 (100) 391 (100)
Age at study entry (y)
 <40 115 (29) 114 (29)
 40–49 170 (43) 189 (49)
 50–59 100 (26) 80 (20)
 60+ 9 (2) 8 (2)
Race/ethnicity
 Caucasian 315 (80) 317 (81)
 Hispanic 6 (2) 5 (1)
 African American 28 (7) 22 (6)
 Asian 10 (2) 7 (2)
 Other 35 (9) 40 (10)
Menopausal status
 Premenopausal 268 (68) 263 (67)
 Peri-/postmenopausal 126 (32) 127 (32)
 Missing 0 (0) 1 (<1)
Tumor size (cm)
 ≤2 103 (26) 96 (24)
 >2 and ≤5 193 (49) 206 (53)
 >5 90 (23) 75 (19)
 Missing 8 (2) 14 (4)
No. of positive nodes
 10–12 162 (41) 160 (41)
 13–15 82 (21) 92 (24)
 16–20 83 (21) 79 (20)
 ≥21 67 (17) 60 (15)
Surgery type
 Mastectomy 310 (79) 301 (77)
 Lumpectomy 81 (20) 87 (22)
 Other* 3 (1) 1 (<1)
 Missing 0 (0) 2 (<1)
Initiated RT
 No 69 (18) 31 (8)
 Yes 325 (82) 360 (92)
If yes, RT technique
 A 200 (62) 226 (62)
 B 83 (25) 85 (24)
 C 26 (8) 32 (9)
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Treatment arm
Characteristic HD-CPB ID-CPB
 Other/Unknown 16 (5) 17 (5)
Abbreviations: HD-CPB = high-dose cyclophosphamide, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and cisplatin; ID-CPB = intermediate-dose
CPB; RT = radiotherapy.
Values are number (percentage).
*
Includes biopsy alone, and no breast surgery (i.e. only axillary dissection), for patients presenting with axillary disease without a clear primary
breast lesion.
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Table 3
Initiation of RT: Results from multivariate logistic regression (n = 774)
Effect More:Less likely to begin RT
OR
(95% CI) p
Treatment arm ID:HD 2.66
(1.65–4.27)
<0.0001






Surgery Nonmastecomy: mastectomy 2.10
(1.12–3.94)
0.02
Tumor ER status Negative: positive 1.72
(1.06–2.78)
0.03
Race × age interaction 0.07
 Age <50 y Non-AA:AA 1.83
(0.76–4.41)
 Age ≥50 y Non-AA:AA 9.43
(2.08–43.48)
Abbreviations: AA= African American; ER = estrogen receptor. other abbreviations as in Table 1.
*
Main effects of race and age tested in the absence of the interaction term.
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Table 4
Incidence of RT interruption by RT technique and type of surgery
Mastectomy Nonmastectomy†
RT technique n % with interruption n % with interruption
Total patients who began RT* 525 17 158 15
A: Tangents
 A1: IMN <30 Gy 145 17 40 13
 A2: IMN ≥30 Gy 160 13 79 15
B: Separate IMN field 137 20 31 23
C: Chest wall electrons 58 26 0 —
Other/unknown 25 0 8 0
Abbreviation: IMN = internal mammary nodes. Other abbreviations as in Table 1.
*
Excludes patients with missing data on type of surgery.
†
Lumpectomy, n = 155; axillary dissection, n = 3.
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Table 5
Reasons for RT modification by treatment arm
Treatment arm
Reason HD ID Total
RT modified 94 (100) 51 (100) 145 (100)
Reason for modification*
 Toxicity from RT 15 (16) 17 (33) 32 (22)
 Toxicity from chemotherapy 37 (40) 3 (6) 40 (28)
 Patient noncompliance 2 (2) 0 2 (1)
 Scheduling difficulties/mechanical problems 6 (6) 7 (14) 13 (9)
 Complicating medical conditions 20 (21) 8 (16) 28 (19)
 Other 14 (15) 16 (31) 30 (21)
Abbreviations as in Table 1.
Values are number (percentage).
*
Taken from data sheets submitted, usually not containing detailed information; thus the categorization may not be specific.













Marks et al. Page 21
Table 6
Incidence of noncompletion of RT by RT technique and type of surgery
Mastectomy Nonmastectomy
RT technique n % terminated early n % terminated early
Total patients who began RT* 505 6 151 5
A: Tangents
 A1: IMN <30 Gy 140 5 36 8
 A2: IMN ≥30 Gy 152 6 79 5
B: Separate IMN field 132 3 29 0
C: Chest wall electrons 56 14 0 —
Other/unknown 25 8 7 0
Abbreviations as in Tables 1 and 4.
*
Excludes patients with missing data on type of surgery and RT completion status.
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Table 7








 Grade 2 72 (22) 98 (27)
 Grade 3 8 (2) 22 (6)
 Grade 4 0 2 (<1)
Lung
 Grade 2 8 (2) 1 (<1)
 Grade 3 13 (4) 1 (<1)
 Grade 4 2 (<1) 0
Leukopenia
 Grade 2 17 (5) 17 (5)
 Grade 3 6 (2) 6 (2)
 Grade 4 0 0
Anemia
 Grade 2 19 (6) 1 (<1)
 Grade 3 7 (2) 0
 Grade 4 1 (<1) 0
Thrombocytopenia
 Grade 2 15 (5) 1 (<1)
 Grade 3 11 (3) 0
 Grade 4 2 (<1) 1 (<1)
Upper gastrointestinal
 Grade 2 2 (1) 0
 Grade 3 1 (<1) 0
 Grade 4 0 0
Abbreviations as in Table 1.
Values are number (rate [%]).
*
Grade ≥2 only. Data available in 681 patients. Some patients with more than one toxicity scored. Events scored as “radiation-related,” but
certainly may be related to chemotherapy. Other minor toxicities with <1% incidence are not shown (e.g., breast edema).
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